New combo therapy offers hope for Tough-to-Treat blood cancer
NCT ID NCT06923488
First seen May 13, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This study is for people with myelodysplastic syndromes (MDS) whose disease has returned or not responded to standard treatment. Researchers are testing a combination of two drugs, leflunomide and decitabine, to find the safest and most effective doses. The goal is to control the disease, not cure it, and participants will need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West Virginia University Cancer Institute
RECRUITINGMorgantown, West Virginia, 26506, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.